AC Immune SA has synthesized new heterocyclic modulators acting as NLRP3 inflammasome inhibitors. As such, they are reported to be potentially useful for the treatment of asthma, atherosclerosis, obesity, gout, cryopyrin-associated periodic syndromes, nonalcoholic fatty liver disease (NAFLD), Parkinson’s and Alzheimer’s disease, among others.
Abarceo AB has developed new voltage-dependent anion-selective channel protein 1 (VDAC1) inhibitors reported to be useful for the treatment of diabetes type 1 and 2.
A recent Merck Sharp & Dohme LLC patent details new substituted isoquinoline derivatives acting as tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 (TCPTP) inhibitors potentially useful for the treatment of cancer.
Work at Childrens Medical Center Corp. has led to the identification of new gasdermin-D (GSDMD) activators reported to be useful for the treatment of cancer.
Akebia Therapeutics Inc. has identified new derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate acting as prolyl 4-hydroxylase (PHD) inhibitors.
A Black Diamond Therapeutics Inc. patent describes new alkyne-substituted quinazoline derivatives acting as EGFR (HER1; erbB1) inhibitors particularly, EGFR mutant inhibitors, potentially useful for the treatment of cancer.
Biosplice Therapeutics Inc. has prepared and tested 4-alkoxypyrrolo[2,1-F][1,2,4]triazines acting as dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors potentially useful for the treatment of Alzheimer’s disease.
Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful for the treatment of psychiatric disorders.
RSS